Abstract
Monoclonal antibody (MAb) FC-2.15 recognizes Lewis × antigen (Le×-Ag) expressed on the cell surface of most human breast cancer cells. FC-2.15 displays important human complement (C′)-mediated cytotoxicity (CMC) against its target cells. In this study the reactivity of FC-2.15 against drug resistant-breast cancer cells was investigated, as well as the possibility to combine the antitumor activities of this MAb with adriamycin (Adr) or taxol. Since resistant clones with altered expression of tumor-associated antigens usually emerge after chemotherapy, the expression of Le×-Ag was analyzed in AdrR MCF-7 breast cancer cells (Adr resistant subline) and in tumor samples from nine patients with locally advanced breast carcinoma who were treated with FEC chemotherapy. A flow cytometry assay showed that most of AdrR MCF-7 cells, as well as wild type (WT) cells, expressed Le×-Ag; however, the Le× epitope is probably bound to different backbones in these cells. When the cytotoxic ability of FC-2.15 against WT and AdrR MCF-7 cells was compared, it was found that a 90 min treatment with FC-2.15 plus C′ induced similar CMC against both cell lines. An important cytolysis was obtained at 5 µg/ml FC-2.15, reaching a plateau at 25 µg/ml, at which cell population was diminished to 21.1% for WT and 27.9 for AdrR MCF-7 cells. Regarding human tumors, Le×-Ag expression was evaluated in samples obtained before and in most cases after chemotherapy, and it could be observed that: 1) before treatment, tumor samples from all patients analyzed (responders and non-responders to chemotherapy) were FC-2.15-positive; 2) the presence of Le×-Ag was not modified after treatment. The combined action of Adr or taxol with FC-2.15 was then evaluated. WT and AdrR MCF-7 cells were cultured with Adr or taxol followed by an incubation with different FC-2.15 concentrations plus C′. When the effect of Adr alone was determined, ID50 were 1 × 10-7 M for WT and 4.2 × 10-5 M for AdrR MCF-7 cells. The cytotoxic ability of taxol alone was also tested, and ID50 were 6.4 × 10-9 M for WT and 3.1 × 10-6 M for AdrR MCF-7 cells. When FC-2.15 was added to Adr or taxol, the cytotoxicity of the drug-FC-2.15 combined treatment was always higher than the isolated effects, showing additive cytotoxicity at the different concentrations tested and with both cell lines. Our results suggest that FC-2.15 may be a useful agent against breast tumor cells which survive chemotherapy with Adr or taxol.
Similar content being viewed by others
References
Mordoh J, Leis S, Bravo AI, Podhajcer O, Ballaré C, Capurro M, Kairiyama C, Bover L: Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias. Int J Biol Markers 9: 125–134, 1994
Capurro M, Bover L, Portela P, Livingston P, Mordoh J: FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis ×hapten. Cancer Immunol Immunother (in press)
Ballaré C, Barrio M, Portela P, Mordoh J: Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells. Cancer Immunol Immunother 41: 15–22, 1995
Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C: Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother 17: 151–160, 1995
McClean S, Hill BT: An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim Biophys Acta 1114: 107–127, 1992
Fairchild C, Ivy SP, Kao-Shan C, Whang-Peng J, Rosen N, Israel M, Melera P, Cowan K, Goldsmith M: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141–5148, 1987
Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427, 1993
Salmon S, Grogan T, Miller T, Scheper R, Dalton W: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81: 696–701, 1989
Vickers PJ, Dickson RB, Shoemaker R, Cowan KH: A multidrug– resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886–892, 1988
Whelan RD, Hill BT: Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation. Breast Cancer Res Treat 26: 23–39, 1993
Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409–1415, 1973
Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnati A, Lema B, Schiaffi J, Yomha R, Mordoh J: Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 19: 47–56, 1991
Bravo AI, Sorin I, Guman N, Mordoh J: Carcinoembryonic antigen and differentiation in human breast cancer. J Exp Clin Cancer Res 4: 3–10, 1985
Hakomori S: Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45: 2405–2414, 1985
Kim YS: Altered glycosylation of mucin glycoproteins in colonic neoplasia. J Cell Biochem (Suppl) 16G: 91–96, 1992
Kim YS: Carbohydrate antigen expression in colorectal cancer. Sem Cancer Biol 1: 189–197, 1990
Ho SB, Kim YS: Carbohydrate antigens on cancer-associated mucin-like molecules. Sem Cancer Biol 2: 389–400, 1991
Urdal DL, Brentnall TA, Bernstein ID, Hakomori SI: A granulocyte reactive monoclonal antibody, IG10, identifies the galb1–4 (Fuca1–3) GlcNAc (×determinant) expressed in HL60 cells on both glycolipid and glycoprotein molecules. Blood 62: 1022–1026, 1983
Singhal AK, Orntoft TF, Nudelman E, Nance S, Schibig L, Stroud MR, Clausen H, Hakomori S: Profiles of Lewis×-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma. Cancer Res 50: 1375–1380, 1990
Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry. Blood group-related antigens. Int J Cancer (in press)
D'Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163–177, 1989
Hudis C, Seldman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L: Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 23: 58–64, 1996
Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552–9556, 1993
Rights and permissions
About this article
Cite this article
Ballaré, C., Portela, P., Schiaffi, J. et al. Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15. Breast Cancer Res Treat 47, 163–170 (1998). https://doi.org/10.1023/A:1005949118919
Issue Date:
DOI: https://doi.org/10.1023/A:1005949118919